Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis

Rina Aharoni, Raya Eilam, Nofar Schottlender, Lihi Radomir, Sandra Leistner-Segal, Tali Feferman, Dana Hirsch, Michael Sela, Ruth Arnon

Research output: Contribution to journalArticlepeer-review

Abstract

To identify the mechanisms relevant for the therapeutic effect of glatiramer acetate (GA), we studied T- and B- regulatory cells as well as GM-CSF expression in mice recovered from experimental autoimmune encephalomyelitis (EAE). Selective depletion of Tregs reduced but did not eliminate the ability of GA to ameliorate EAE, indicating a role for additional immune-subsets. The prevalence of Bregs in the periphery and the CNS of EAE-mice increased following GA-treatment. Furthermore, GA downregulated the pathological expression of GM-CSF, on both the protein and mRNA levels. These findings corroborate the broad immunomodulatory mechanism of action of GA in EAE/MS.

Original languageEnglish
Article number577281
JournalJournal of Neuroimmunology
Volume345
DOIs
StatePublished - 15 Aug 2020
Externally publishedYes

Keywords

  • B-regulatory cells (Bregs)
  • Experimental autoimmune encephalomyelitis
  • Glatiramer acetate (GA)
  • Granulocyte-macrophage colony-stimulating factor (GM-CSF)
  • Multiple sclerosis
  • T-regulatory cells (Tregs)

Fingerprint

Dive into the research topics of 'Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis'. Together they form a unique fingerprint.

Cite this